Delaney Fragale, PA
Physician Assistant · Amherst, NYNPI 1578030862
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $22,096 of the $32,596 with a category attached, or 67.8%. 40 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 31.3% of the total. 2025 is the largest year on record at $13,336, 3.0 times the $4,501 reported in 2021. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,051 payments — averaging $31.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$10K
- AbbVie$5K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Lundbeck LLC$1K
- plus $10K from 34 others
What the payments were for
- Consulting fees$1,7005%
- Speaking & faculty fees$8,12825%
- Travel & lodging$2001%
- Food & beverage$22,09668%
- Education$4721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$7,985
- VRAYLAR$2,855
- CAPLYTA$611
- SPRAVATO$479
- QELBREE$472
- ARISTADA$415
- INGREZZA$375
- AUSTEDO$250
- REXULTI$229
- Auvelity$224
- UZEDY$167
- ABILIFY MAINTENA$125
- Azstarys$125
- COBENFY$125
- INVEGA SUSTENNA$111
- INVEGA TRINZA$111
- ARISTADA INITIO$104
How this compares
$32,596 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 57 | $739,848 |
| Austedo XrDeutetrabenazine | 92 | $638,570 |
| IngrezzaValbenazine Tosylate | 45 | $392,037 |
| CaplytaLumateperone Tosylate | 143 | $243,145 |
| NuplazidPimavanserin Tartrate | 33 | $211,974 |
| RexultiBrexpiprazole | 136 | $202,964 |
| VraylarCariprazine Hcl | 128 | $197,916 |
| TrintellixVortioxetine Hydrobromide | 239 | $172,563 |
| AuvelityDextromethorphan Hbr/Bupropion | 76 | $86,752 |
| NuedextaDextromethorphan Hbr/Quinidine | 28 | $52,206 |
| QuviviqDaridorexant Hcl | 67 | $32,319 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,640 |
| Aripiprazole | 476 | $19,162 |
| BelsomraSuvorexant | 34 | $14,317 |
| Lisdexamfetamine Dimesylate | 39 | $12,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $10,196 | $1,378,418149 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,772 | $392,03745 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,754 | $243,145143 claims |
| Acadia Pharmaceuticals IncNuplazid | $232 | $211,97433 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,220 | $202,964136 claims |
| AbbVieVraylar | $4,762 | $197,916128 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $661 | $172,563239 claims |
| Axsome Therapeutics, Inc.Auvelity | $786 | $86,75276 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $532 | $52,20628 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $359 | $32,31967 claims |
| Alkermes, Inc.Lybalvi | $1,152 | $19,64012 claims |
| MerckBelsomra | $39 | $14,31734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Amherst
- Michael AsbachAmherst$962K
- Madeline SliszAmherst$101K
- Rachel AllenAmherst$54K
- Lauren JendraszekAmherst$40K
- Henry YuBronx$1M
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.